Combined hepatocellular carcinoma and cholangiocarcinoma: Clinical features, treatment modalities, and prognosis

Annals of Surgical Oncology

Volumn 19, Issue 9, 2012, Pages 2869-2876

  Yin, Xin ^a   Zhang, Bo Heng ^a   Qiu, Shuang Jian ^a   Ren, Zheng Gang ^a   Zhou, Jian ^a   Chen, Xiao Hong ^a   Zhou, Ying ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CHEMOEMBOLIZATION; CONTROLLED STUDY; FEMALE; HEPATITIS; HEPATITIS VIRUS; HISTOPATHOLOGY; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION;

ADULT; AGED; ALPHA-FETOPROTEINS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84867404712     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2328-0     Document Type: Article

References (19)

1. Gibson JB. Histological typing of tumours of the liver, biliary tract and pancreas. In: Sobin LH. International histological classification of tumours. Geneva: World Health Organization; 1978. p. 19-30.
2. Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040-6.
3. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25:647-55.
4. Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120-5.
5. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48, 900 necropsies. Cancer. 1954;7:462-503.
6. Sun HC, Tang ZY, Ma ZC, et al. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol. 2005;131:284-8.
7. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458-65.
8. Yang BW, Zou J, Xia JL, et al. Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation. Eur J Radiol. 2011;79:196-200.
9. Fan J, Wu ZQ, Zhou J, et al. Hepatocellular carcinoma associated with tumor thrombosis in the portal vein: the effects of different treatments. Hepatobiliary Pancreat Dis Int. 2003;2:513-9.
10. Lee CC, Wu CY, Chen JT, et al. Comparing combined hepatocellularcholangiocarcinoma and cholangiocarcinoma: a clinicopathological study. Hepatogastroenterology. 2002;49:1487-90.
11. Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283-7.
12. Ng IO, Shek TW, Nicholls J, et al. Combined hepatocellular cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol. 1998;13:34-40.
13. Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967;67:337-48.
14. Lee JH, Chung GE, Yu SJ et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol. 2011;45:69-75.
15. Taguchi J, Nakashima O, Tanaka M, et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996;11:758-64.
16. Kim KH, Lee SG, Park EH, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16:623-9.
17. Chantajitr S, Wilasrusmee C, Lertsitichai P, et al. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population. J Hepatobiliary Pancreat Surg. 2006;13:537-42.
18. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-9.
19. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-71.